DIALYSIS SOLUTIONS CONTAINING PYROPHOSPHATES
    1.
    发明申请
    DIALYSIS SOLUTIONS CONTAINING PYROPHOSPHATES 有权
    包含磷酸盐的透析溶液

    公开(公告)号:US20100119618A1

    公开(公告)日:2010-05-13

    申请号:US12687536

    申请日:2010-01-14

    IPC分类号: A61K33/42

    摘要: Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high pressure, ultra-violet, filtration or combination thereof. The dialysis solution can be in the form of a concentrate.

    摘要翻译: 提供了包含焦磷酸盐的透析溶液以及制备和使用透析溶液的方法。 在一个实施方案中,本公开提供了包含稳定和治疗有效量的焦磷酸盐的透析溶液。 透析溶液可以例如使用高压釜,蒸汽,高压,紫外线,过滤或其组合的技术进行灭菌。 透析溶液可以是浓缩物的形式。

    Methods for diagnosing renal disorders
    2.
    发明授权
    Methods for diagnosing renal disorders 有权
    诊断肾功能障碍的方法

    公开(公告)号:US08110367B2

    公开(公告)日:2012-02-07

    申请号:US12221371

    申请日:2008-08-01

    IPC分类号: G01N33/53

    摘要: The present invention relates to methods for diagnosing the presence and progress of pathologies characterized by an accumulation of the extracellular matrix components by measuring the level of Connective Tissue Growth Factor (CTGF) in a sample. The method of the present invention is directed to diagnosing kidney fibrosis and associated renal disorders, in particular, complications associated with diabetes, hyperglycemia, and hypertension.

    摘要翻译: 本发明涉及通过测量样品中结缔组织生长因子(CTGF)的水平来诊断特征在于细胞外基质成分积累的病理学的存在和进展的方法。 本发明的方法涉及诊断肾纤维化和相关的肾脏疾病,特别是与糖尿病,高血糖症和高血压相关的并发症。

    METHODS AND COMPOSITIONS FOR REDUCING OR PREVENTING VASCULAR CALCIFICATION DURING PERITONEAL DIALYSIS THERAPY
    3.
    发明申请
    METHODS AND COMPOSITIONS FOR REDUCING OR PREVENTING VASCULAR CALCIFICATION DURING PERITONEAL DIALYSIS THERAPY 审中-公开
    在透析治疗期间减少或预防血管计算的方法和组合物

    公开(公告)号:US20110262555A1

    公开(公告)日:2011-10-27

    申请号:US13092324

    申请日:2011-04-22

    IPC分类号: A61K33/42 A61P9/00 A61P7/08

    摘要: Methods and compositions for reducing, preventing or reducing the progression of calcification in peritoneal dialysis patients are provided. In an embodiment, the present disclosure provides a method comprising administering to a patient during peritoneal dialysis therapy a dialysis solution comprising a therapeutically effective amount of pyrophosphate ranging between about 30 μM and about 400 μM. Formulations of dialysis solutions according to the dose ranges claimed in the present disclosure allow therapeutic amounts of pyrophosphate to be delivered to peritoneal dialysis patients.

    摘要翻译: 提供了减少,预防或减少腹膜透析患者钙化进展的方法和组合物。 在一个实施方案中,本公开提供了一种方法,包括在腹膜透析治疗期间向患者施用包含治疗有效量的焦磷酸盐的透析溶液,其范围在约30μM至约400μM之间。 根据本公开要求的剂量范围的透析溶液的制剂允许将治疗量的焦磷酸盐递送至腹膜透析患者。

    DIALYSIS SOLUTIONS CONTAINING PYROPHOSPHATES
    5.
    发明申请
    DIALYSIS SOLUTIONS CONTAINING PYROPHOSPHATES 有权
    包含磷酸盐的透析溶液

    公开(公告)号:US20090098215A1

    公开(公告)日:2009-04-16

    申请号:US11871018

    申请日:2007-10-11

    IPC分类号: A61K33/42 A61P7/08

    摘要: Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high pressure, ultra-violet, filtration or combination thereof. The dialysis solution can be in the form of a concentrate.

    摘要翻译: 提供了包含焦磷酸盐的透析溶液以及制备和使用透析溶液的方法。 在一个实施方案中,本公开提供了包含稳定和治疗有效量的焦磷酸盐的透析溶液。 透析溶液可以例如使用高压釜,蒸汽,高压,紫外线,过滤或其组合的技术进行灭菌。 透析溶液可以是浓缩物的形式。

    Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases
    6.
    发明授权
    Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases 有权
    CCN3对CCN2的调控及其在纤维化,硬化等疾病中的治疗和诊断潜力

    公开(公告)号:US07780949B2

    公开(公告)日:2010-08-24

    申请号:US11329453

    申请日:2006-01-10

    申请人: Bruce L. Riser

    发明人: Bruce L. Riser

    摘要: The present invention discloses a role of CCN3 in diseases associated with the overexpression of CCN2, which include but are not limited to kidney disease, fibrosis, and cancer. The full length CCN3 protein or fragments thereof or isoforms (or combinations) of CCN3 are involved in these diseases. The isolated and purified CCN3 protein or its fragments or isoforms (or combinations) of CCN3 can be potentially used in the treatment or prevention of these diseases by regulating the expression and/or activity of the CCN2 protein. The level of CCN3 in tissue or body fluids can also be used to predict, diagnose and/or follow the progression of diseases as well as to determine the effectiveness of therapeutic intervention.

    摘要翻译: 本发明公开了CCN3​​在与CCN2的过度表达相关的疾病中的作用,其包括但不限于肾脏疾病,纤维化和癌症。 CCN3的全长CCN3蛋白或其片段或同种型(或组合)参与这些疾病。 通过调节CCN2蛋白的表达和/或活性,CCN3的分离和纯化的CCN3蛋白或其片段或同种型(或组合)可以潜在地用于治疗或预防这些疾病。 组织或体液中CCN3的水平也可用于预测,诊断和/或跟踪疾病进展以及确定治疗干预的有效性。

    CCN3 peptides and analogs thereof for therapeutic use
    7.
    发明授权
    CCN3 peptides and analogs thereof for therapeutic use 有权
    CCN3肽及其类似物用于治疗用途

    公开(公告)号:US08518395B2

    公开(公告)日:2013-08-27

    申请号:US13079693

    申请日:2011-04-04

    申请人: Bruce L. Riser

    发明人: Bruce L. Riser

    IPC分类号: A01N63/00 A01N65/00 A61K38/00

    摘要: The present invention provides a CCN3 peptide for treating a subject in need thereof having an amino acid sequence identified as CCNp37, CCNp38 (human), CCNp38 (mouse), a cysteine-substituted CCNp37, cysteine-substituted CCNp38 (human) or a cysteine-substituted CCNp38 (mouse).

    摘要翻译: 本发明提供了一种CCN3肽,其用于治疗需要其具有鉴定为CCNp37,CCNp38(人),CCNp38(小鼠),半胱氨酸取代的CCNp37,半胱氨酸取代的CCNp38(人)或半胱氨酸取代的CCNp38 取代的CCNp38(小鼠)。

    Methods for diagnosing renal disorders
    8.
    发明申请
    Methods for diagnosing renal disorders 有权
    诊断肾功能障碍的方法

    公开(公告)号:US20090017559A1

    公开(公告)日:2009-01-15

    申请号:US12221371

    申请日:2008-08-01

    IPC分类号: G01N33/566

    摘要: The present invention relates to methods for diagnosing the presence and progress of pathologies characterized by an accumulation of the extracellular matrix components by measuring the level of Connective Tissue Growth Factor (CTGF) in a sample. The method of the present invention is directed to diagnosing kidney fibrosis and associated renal disorders, in particular, complications associated with diabetes, hyperglycemia, and hypertension.

    摘要翻译: 本发明涉及通过测量样品中结缔组织生长因子(CTGF)的水平来诊断特征在于细胞外基质成分积累的病理学的存在和进展的方法。 本发明的方法涉及诊断肾纤维化和相关的肾脏疾病,特别是与糖尿病,高血糖症和高血压相关的并发症。